Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart failure clue: blood test may forecast therapy success

NCT ID NCT07469137

Knowledge-focused Sponsor: Trakya University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a substance called YKL-40 in the blood can help predict how well heart failure patients will respond to cardiac resynchronization therapy (CRT), a special pacemaker. About 51 adults with severe heart failure will have blood samples taken during their routine CRT procedure. Researchers will then check their heart function 6 months later to see if YKL-40 levels are linked to improvement. The goal is to find a simple way to identify who will benefit most from CRT.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

51 people

The number who actually took part.

Started

Mar 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with heart failure who have been decided to undergo CRT treatment at Trakya University Cardiology Clinic

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with heart failure, with an EF ≤35, who remain in heart failure stages 2-3-4 despite optimal medical therapy, and who have LBBB and a QRS duration of at least 130 msec. * Those who agreed to participate in the study * Patients diagnosed with heart failure and who have been monitored, and for whom a permanent pacemaker has been decided due to the presence of a high-degree heart block Exclusion Criteria: * Patients under the age of 18 * Patients not receiving optimal medical treatment * Those who declined to participate in the study * Malignancy patients with an expected survival period of less than 1 year * Patients with chronic inflammatory and rheumatological diseases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac resynchronisation therapy (CRT) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bundle branch block, familial isolated complete right heart failure progressive familial heart block, type 1A systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac resynchronisation therapy (CRT) Hearth failure with reduced ejection fraction (hfref) Left branch bundle block

Contacts and locations

Locations

  • Trakya University

    Edirne, Edirne, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.